🔗 Share this article

Given that America continues making sweeping adjustments to its vaccine guidelines, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccinations during the pandemic and has concentrated on possible deaths after COVID-19 vaccination in her short tenure at the FDA.

Proposed Shifts to Pediatric Immunization Schedule

Public health authorities had intended to reveal radical changes to the pediatric vaccination calendar recently, synchronizing the US with the Danish immunization schedule, sources say – a major change that would place the US at odds with much of the world with no evidence for public health gain. This reveal has been delayed until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this year.

A Shift at the Agency

This interim role might represent a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad consolidate power at the agency – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

Høeg has repeatedly called for ending some pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a country with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – traditionally the domain of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Questions Over Qualifications

The appointee has no obvious background in medication creation, oversight or administrative roles, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She appears not to have the necessary background” for overseeing the drug-regulation department, said Jonathan Howard. “She’s never run a scientific study. She is not versed in leading a sizeable institution. She has no expertise in industry regulation.”

Past directors of CBER would “understand legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who ran CBER have had.”

CDER has an immense range of responsibilities at the FDA, she stated.

“The public just pays attention on the new drug program, but the generic drug division approves thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and other areas, and all of those have to be managed,” Dr. Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial leadership element to the job, which manages in excess of 5,000 staff members. “It’s a massive administrative position, if you do it right,” the former official concluded.

Official Statement and Controversial Initiatives

Regarding inquiries about Høeg’s credentials and whether this assignment indicates increased cooperation among FDA leaders on immunizations, a press secretary said that the “questions rely on incorrect premises”.

“Her experience matches the functions of her position,” the representative stated, noting the time Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg inherits the agency head's controversial fast-track approval initiative, a disputed expedited medication authorization process that reportedly troubled her predecessors. “How are these drugs being chosen for this voucher program? Who makes the decisions?” Howard questioned. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he remarked, “the agency seems to be moving towards more relaxed oversight of most medications, with the exception of vaccines.”

Documented Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if concerning, past, Howard said. She published a research paper using unconfirmed public submissions to determine the incidence of myocarditis after COVID-19 vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the incoming administration encompassed changing regulations for novel immunizations and discontinuing “unnecessary” immunizations, she said after the election on a audio program. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from obtaining COVID-19 vaccines.

“She’s an all-around ideologue who commences with her preconceived notions and reverse-engineers to retrofit the science in a extremely deceptive, fraudulent fashion,” Howard said.

Taking Control and a “Revenge Tour”

Høeg aligned with other dissenters, {like|